HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JTP 4819

a prolyl endopeptidase inhibitor; structure given in first source

Also Known As:

2-((2-(hydroxyacetyl)-1-pyrrolidinyl)carbonyl)-N-(phenylmethyl)-1-pyrrolidinecarboxamide; JTP-4819

Networked: 6 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - JTP 4819: 6

Experts

1.	Lehtonen, Sárka: 1 article (12/2006)
2.	Männistö, Pekka T: 1 article (12/2006)
3.	Puttonen, Katja A: 1 article (12/2006)
4.	Raasmaja, Atso: 1 article (12/2006)

Related Diseases

1.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/03/1996 - "These results suggest that JTP-4819 ameliorates memory impairment due to middle cerebral artery occlusion by restoring the cortical TRH content." 06/03/1996 - "The prolonged escape latency in the Morris water maze task in rats with middle cerebral artery occlusion was also significantly reduced by administration of JTP-4819 (0.3 and 1 mg/kg p.o.). " 06/03/1996 - "Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion." 06/03/1996 - "Administration of JTP-4819 (0.1 and 1 mg/kg p.o for 7 days) significantly prolonged passive avoidance latency, while the latency of rats with middle cerebral artery occlusion receiving the vehicle was significantly shorter than that of sham-operated rats. "
2.	Amnesia (Dissociative Amnesia) 09/01/1995 - "In the one-trial passive avoidance test in rats with scopolamine-induced amnesia, JTP-4819 significantly prolonged the retention time when administered orally at doses of 1 and 3 mg/kg 1 hr before acquisition or at 3 and 10 mg/kg 1 hr before retention. " 09/01/1995 - "In addition, coadministration of JTP-4819 and substance P, arginine-vasopressin or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced amnesia. "
3.	Memory Disorders (Memory Loss) 03/01/1997 - "Administration of JTP-4819 (1 mg/kg, p.o.) for 14 days improved this memory deficit in aged rats, as shown by the decrease in escape latency and path length. "
4.	Alzheimer Disease (Alzheimer's Disease) 02/01/1997 - "Taken together, these unique and potent pharmacological actions of JTP-4819 suggest that it may have the potential to be used for treating Alzheimer's disease." 01/01/1998 - "In this report, the pharmacological actions of JTP-4819, a novel specific prolyl endopeptidase (PEP) inhibitor devised for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, neuropeptidergic and cholinergic neurons, and memory-related behavior in rats. " 02/01/1997 - "A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease." 02/01/1997 - "The pharmacological actions of JTP-4819, a new prolyl endopeptidase (PEP) inhibitor targeted for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, brain neurotransmitters, and memory-related behaviour in rats. "
5.	Neuroblastoma 12/01/2006 - "We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells. "

Related Drugs and Biologics

1.	Scopolamine (Hyoscine)
2.	Thyrotropin-Releasing Hormone (Protirelin)
3.	Substance P
4.	Arginine Vasopressin (Argipressin)
5.	Prolyl Oligopeptidases
6.	Neurotransmitter Agents (Neurotransmitter)
7.	Reactive Oxygen Species (Oxygen Radicals)
8.	Oxidopamine (6 Hydroxydopamine)
9.	Glyceraldehyde-3-Phosphate Dehydrogenases (GAPD)
10.	Cytarabine (Cytosar-U)